1-5 of 5
Paul A. Beavis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G. House, Peter Savas, Junyun Lai, Amanda X.Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (2): 487–504.
https://doi.org/10.1158/1078-0432.CCR-19-1868
Published: 15 January 2020
View article titled, Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Open the PDF for Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

Clare Y. Slaney, Bianca von Scheidt, Alexander J. Davenport, Paul A. Beavis, Jennifer A. Westwood, Sherly Mardiana, David C. Tscharke, Sarah Ellis, H. Miles Prince, Joseph A. Trapani, Ricky W. Johnstone, Mark J. Smyth, Michele W. Teng, Aesha Ali, Zhiya Yu, Steven A. Rosenberg, Nicholas P. Restifo, Paul Neeson, Phillip K. Darcy, Michael H. Kershaw
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2478–2490.
https://doi.org/10.1158/1078-0432.CCR-16-1860
Published: 14 May 2017
View article titled, Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Open the PDF for Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting in another window
Includes: Supplementary data
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark J. Smyth, Michael H. Kershaw, Phillip K. Darcy
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (20): 5636–5646.
https://doi.org/10.1158/1078-0432.CCR-13-0458
Published: 14 October 2013
View article titled, Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Open the PDF for Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells in another window
Includes: Supplementary data